Navigation Links
Statins Market to 2018 - Weak Product Pipeline and Shift of Focus towards Combination Therapies will Lead to Erosion of Brand Share
Date:7/29/2013

DUBLIN, July 29, 2013 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/49ljmx/statins_market_to) has announced the addition of the "Statins Market to 2018 - Weak Product Pipeline and Shift of Focus towards Combination Therapies will Lead to Erosion of Brand Share" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769)

This report provides insights into the global statins market until 2018. The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by a team of industry experts. The report provides an in-depth analysis of the global statins market for dyslipidemia.

The report examines the dyslipidemia treatment usage patterns in the US, the top five countries of Europe (The UK, France, Germany, Spain and Italy), and Japan. In addition to the global market landscape for statins, the report also provides details of the geographical distribution of statins sales in the major markets, including the US, the top five countries of Europe, and Japan.

The report also includes insights into the statins R&D product pipeline, and explores the competitive landscape, including major players in the statins market. Finally, the report also includes analysis on mergers and acquisitions (M&A) and licensing and co-development deals that have taken place in the statins market.

Statins have dominated the global dyslipidemia therapeutics market for the last few decades. The National Cholesterol Education Program (NECP) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guidelines have recommended the use of statins as the first choice of pharmacotherapy for the treatment of dyslipidemia.

The global statins market, valued at $20.5 billion in 2011, is forecast to decline at a negative Compound Annual Growth Rate (CAGR) of 7.2% over the next seven years, to reach $12.2 billion by 2018. The highly consolidated statins market is expected to become increasingly competitive in the forecast period, with the patent expiries of (atorvastatin calcium), Vytorin (Ezetimibe/simvastatin), Lescol (fluvastatin) and Crestor (rosuvastatin), followed by severe generic erosion. GBI Research estimates that the generic sector in the global statins market will grow significantly in the future and will pose tough competition to new molecules.

Scope

- Annualized market data for the statins market from 2004 to 2011, with forecasts to 2018

- Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment-seeking population, diagnosis population and prescription population

- Share of generics in the global statins market

- Key drivers and restraints that have had a significant impact on the global statins market

- The competitive landscape of the global statins market, including top companies benchmarking. The key companies studied in this report are Pfizer, AstraZeneca, Merck and Novartis

- Key M&A activities and licensing agreements that took place in the statins market

Reasons to buy

- Align their product portfolio to the markets with high growth potential

- Build effective strategies to launch their pipeline products by identifying potential geographies

- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps

- Develop key strategic initiatives by studying the key strategies of top competitors

- Devise more tailored country-specific strategies through the understanding of key drivers and barriers and the market potential of each indication for different territories

- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth

- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious

For more information visit  http://www.researchandmarkets.com/research/49ljmx/statins_market_to

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
U.S. Fax: +1-646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals


'/>"/>
SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. China Heart Valve Market and Heart Lung Machine Industry Global Analysis in New Research Reports
2. The Global Proteomics Market to Grow At A CAGR Of 14.43 Percent over the Period 2012-2016
3. Global Vascular Stents Market 2012-2016 Report with Abbott Laboratories, Medtronic Inc. and Boston Scientific Corp. Dominating
4. Indegene builds on Aptilon acquisition to launch new iMCM framework for enhanced Enterprise-wide Multichannel Marketing (MCM) deployment.
5. Cepheid Receives FDA Market Authorization for Xpert MTB/RIF
6. Femtosecond Lasers for Cataract Surgery: Market Shares, Strategies, and Forecasts, Worldwide, Nanotechnology, 2013 to 2018
7. DNA Sequencing 2013 Research Report: Market Developments, Growth Areas and Opportunities
8. Frost & Sullivan Hosts Analyst Briefing: An Outlook of Azerbaijan and Iran Healthcare Markets
9. The Global Market for Intravascular Ultrasound Tools and Ancillary Equipment
10. Computational Biology Market - Global Industry Analysis, Size, Share, Growth, Trend
11. Water Treatment Industry Reports: Equipment Research for US & Global Wastewater Treatment Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... April 28, 2016 ... George Phillips und Stephen Schmidt ... ArisGlobal®, ein führender Anbieter cloudbasierter ... heute bekannt, dass neue Führungskräfte zum Team ... sind, die vielfältige Erfahrungen mitbringen.  Dies wird ...
(Date:4/28/2016)... 2016 Dr. Vivek Ahuja , ... Ste phen Schmidt ... provider of cloud-based software solutions for life sciences, today announced key ... a wealth of insight to a growing business.  This will bolster ... George Phillips joined ArisGlobal in the position of Vice ...
(Date:4/28/2016)... 2016 TapImmune,Inc. (TPIV), a ... and gene-based immunotherapeutics and vaccines for the treatment of cancer ... the 3rd Annual Growth Capital Expo to be ... at Caesars Palace in Las Vegas, Nevada.  The Company ... 4 th by Dr. John N. Bonfiglio ...
Breaking Medicine Technology:
(Date:4/30/2016)... ... ... Orlando-based Maximized Living has selected Dr. Nick Wilson of Indianapolis to support members ... of Maximized Living doctors at the London Olympics in 2012, U.S. wrestlers won four ... largest contingent of elite chiropractors to Rio to support and care for members of ...
(Date:4/29/2016)... ... April 29, 2016 , ... Since launching its annual ... foundation serving the footwear industry, has broken all previous participation records in its ... across 23 states during the months of April and May, the 2016 Footwear ...
(Date:4/29/2016)... , ... April 29, 2016 , ... On Tuesday, April ... across the Southeast, celebrated the signature of Gov. Nathan Deal on SB 258, the ... Duncan (R - Cumming), offers a 70% tax credit to individuals and corporations which ...
(Date:4/29/2016)... ... April 29, 2016 , ... Conditions were ideal for ... Island Park on Sunday, with sunny skies, a light breeze and temperatures in the ... , The 5k Run and Walk and 1-mile walk were held to ...
(Date:4/29/2016)... ... 2016 , ... The Wharton School of the University ... of the 2016 Wharton Business Plan Competition —as well as the Wharton ... the Committee Award for Most ‘Wow Factor,’ making them the first team in ...
Breaking Medicine News(10 mins):